ZA906753B - Treatment of chronic inflammatory conditions - Google Patents

Treatment of chronic inflammatory conditions

Info

Publication number
ZA906753B
ZA906753B ZA906753A ZA906753A ZA906753B ZA 906753 B ZA906753 B ZA 906753B ZA 906753 A ZA906753 A ZA 906753A ZA 906753 A ZA906753 A ZA 906753A ZA 906753 B ZA906753 B ZA 906753B
Authority
ZA
South Africa
Prior art keywords
treatment
chronic inflammatory
inflammatory conditions
patient
abnormally high
Prior art date
Application number
ZA906753A
Other languages
English (en)
Inventor
John Lawson Stanford
Lawson Stanford John
Graham Arthur William Rook
Arthur William Rook Graham
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London filed Critical Univ London
Publication of ZA906753B publication Critical patent/ZA906753B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Treatment Of Sludge (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA906753A 1989-08-25 1990-08-24 Treatment of chronic inflammatory conditions ZA906753B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898919321A GB8919321D0 (en) 1989-08-25 1989-08-25 Treatment of chronic inflammatory conditions

Publications (1)

Publication Number Publication Date
ZA906753B true ZA906753B (en) 1991-06-26

Family

ID=10662094

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA906753A ZA906753B (en) 1989-08-25 1990-08-24 Treatment of chronic inflammatory conditions

Country Status (13)

Country Link
US (1) US5833996A (ja)
EP (1) EP0489072B1 (ja)
JP (1) JP2987197B2 (ja)
AT (1) ATE135588T1 (ja)
AU (1) AU644813B2 (ja)
CA (1) CA2065286C (ja)
DE (1) DE69026094T2 (ja)
DK (1) DK0489072T3 (ja)
FI (1) FI920795A0 (ja)
GB (2) GB8919321D0 (ja)
NO (1) NO920722L (ja)
WO (1) WO1991002542A1 (ja)
ZA (1) ZA906753B (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
DK0556248T3 (da) * 1990-11-08 1997-10-27 Univ London Mycobacterium som adjuvans til antigener
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
AUPO359396A0 (en) * 1996-11-13 1996-12-05 Amrad Operations Pty. Limited A method of treatment and pharmaceutical compositions useful for same
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
DE69734461T2 (de) * 1996-12-18 2006-07-06 Stanford Rook Ltd. Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
IL132145A (en) * 1997-04-01 2005-11-20 Borody Thomas J Compositions for treating inflammatory bowel disease and uses thereof
EP1002110B2 (en) 1997-08-05 2009-07-29 Stressgen Biotechnologies Corporation Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
GB9723630D0 (en) * 1997-11-07 1998-01-07 Stanford Rook Ltd M.vaccae preparation and its use
HUP0100352A2 (hu) * 1997-12-23 2001-06-28 Genesis Research & Development Corporation Limited Mycobacterium vaccaeből származó kompozíciók és eljárások ezek alkalmazására
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
GB9903539D0 (en) * 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
EP1206190A1 (en) * 1999-08-06 2002-05-22 Corixa Corporation Vaccines for the treatment of autoimmune disease
CA2396384A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
EE200200709A (et) 2000-06-26 2004-08-16 Stressgen Biotechnologies Corporation Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
KR20030074787A (ko) 2001-02-05 2003-09-19 스트레스젠 바이오테크놀러지스 코포레이션 Ｂ형 간염 바이러스 치료
GB0106987D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeuitic agent
WO2003063759A2 (en) 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2487198A1 (fr) * 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
GB8917256D0 (en) * 1989-07-28 1989-09-13 Univ London Biological preparation and its use
DK0556248T3 (da) * 1990-11-08 1997-10-27 Univ London Mycobacterium som adjuvans til antigener

Also Published As

Publication number Publication date
JPH05501870A (ja) 1993-04-08
WO1991002542A1 (en) 1991-03-07
ATE135588T1 (de) 1996-04-15
GB9203904D0 (en) 1992-04-15
DE69026094D1 (de) 1996-04-25
EP0489072B1 (en) 1996-03-20
GB2252044A (en) 1992-07-29
GB8919321D0 (en) 1989-10-11
GB2252044B (en) 1993-09-22
EP0489072A1 (en) 1992-06-10
JP2987197B2 (ja) 1999-12-06
US5833996A (en) 1998-11-10
NO920722D0 (no) 1992-02-24
AU6289790A (en) 1991-04-03
DE69026094T2 (de) 1996-08-22
AU644813B2 (en) 1993-12-23
CA2065286C (en) 2000-05-16
FI920795A0 (fi) 1992-02-24
CA2065286A1 (en) 1991-02-26
NO920722L (no) 1992-04-24
DK0489072T3 (da) 1996-04-15

Similar Documents

Publication Publication Date Title
GB8919321D0 (en) Treatment of chronic inflammatory conditions
AP9901670A0 (en) A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease.
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
AU4297685A (en) Compositions for the allevation, treatment and diagnosis of arthritic disease and related conditions
DE69905368D1 (en) Oxydiertes thymosin beta 4
EP0269408A3 (en) Tgf-beta in the treatment of inflammatory disorders
IT1096291B (it) Corpo di carbonio in forma di una placca,e procedimento per la sua fabbricazione
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
CA2064029A1 (en) Use of mycobacterium vaccae in the prevention of aids
WO1998019945A3 (de) Tablettenprüfgerät
IT8984980A0 (it) Procedimento per la realizzazione di cingoli in gomma e cingolo cosi'.
ES269428U (es) Disposicion de napa.
Hobo Formula for adjusting the horizontal condylar path of the semiadjustable articulator with interocclusal records. Part I: Correlation between the immediate side shift, the progressive side shift, and the Bennett angle
PH25029A (en) 0(-(2,3-di(c1-c4 alkoxy)ethylamino)-b-cyanostyrene and b-nitrostyrene compounds and method for the preparation thereof
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
CA2273848A1 (en) Mycobacterium vaccae for down-regulation of the th2 activity of the immune system
IE900786L (en) Assay for and treatment of autoimmune diseases
Granstein Psoriasis: further evidence of a key role for leukocytes.
Romagnani et al. Human Th1 and Th2 cells: Regulation of development and role in protection and disease
EP0136093A3 (en) Anti-cancer factors
Kalankhodzhaev et al. Tuberculosis relapses in senile and elderly persons and their epidemiological danger.
Babich et al. Heat Treatment of Railroad Rails
Karolik et al. THE EFFECT OF ELASTIC TENSILE STRAIN ON THE THERMO E. M. F. OF PARAMAGNETIC CU-NI ALLOYS
Boles Phenytoin ophthalmoplegia.